Doximity, Inc.
DOCS · NYSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.92 | 0.99 | -1.95 | 0.10 |
| FCF Yield | 2.46% | 3.55% | 2.77% | 1.42% |
| EV / EBITDA | 44.21 | 27.13 | 45.15 | 70.88 |
| Quality | ||||
| ROIC | 17.34% | 13.95% | 10.59% | 17.49% |
| Gross Margin | 90.20% | 89.34% | 87.24% | 88.42% |
| Cash Conversion Ratio | 1.22 | 1.25 | 1.59 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.82% | 11.44% | 26.52% | 43.45% |
| Free Cash Flow Growth | 49.61% | 2.81% | 43.47% | 54.25% |
| Safety | ||||
| Net Debt / EBITDA | -0.82 | -0.45 | -1.05 | -0.94 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 10.45 | 0.00 |
| Cash Conversion Cycle | 73.28 | 63.33 | 119.48 | 81.89 |